151 related articles for article (PubMed ID: 19792961)
21. Cabazitaxel for the treatment of prostate cancer.
Michielsen DP; Braeckman JG; Denis L
Expert Opin Pharmacother; 2011 Apr; 12(6):977-82. PubMed ID: 21406025
[TBL] [Abstract][Full Text] [Related]
22. Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium.
Harzstark AL; Rosenberg JE; Weinberg VK; Sharib J; Ryan CJ; Smith DC; Pagliaro LC; Beer TM; Liu G; Small EJ
Cancer; 2011 Jun; 117(11):2419-25. PubMed ID: 24048789
[TBL] [Abstract][Full Text] [Related]
23. Improving outcomes with recent advances in chemotherapy for castrate-resistant prostate cancer.
Sartor O; Halstead M; Katz L
Clin Genitourin Cancer; 2010 Dec; 8(1):23-8. PubMed ID: 21208852
[TBL] [Abstract][Full Text] [Related]
24. A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancer.
Cetnar J; Wilding G; McNeel D; LoConte NK; McFarland TA; Eickhoff J; Liu G
Urol Oncol; 2013 May; 31(4):436-41. PubMed ID: 21481618
[TBL] [Abstract][Full Text] [Related]
25. New and emerging agents for the treatment of castration-resistant prostate cancer.
Higano CS; Crawford ED
Urol Oncol; 2011; 29(6 Suppl):S1-8. PubMed ID: 22074657
[TBL] [Abstract][Full Text] [Related]
26. Docetaxel in the treatment of metastatic castration-resistant prostate cancer (mCRPC): an observational study in a single institution.
Schallier D; Decoster L; Braeckman J; Fontaine C; Degrève J
Anticancer Res; 2012 Feb; 32(2):633-41. PubMed ID: 22287756
[TBL] [Abstract][Full Text] [Related]
27. Preliminary results of tranilast treatment for patients with advanced castration-resistant prostate cancer.
Izumi K; Mizokami A; Shima T; Narimoto K; Sugimoto K; Kobori Y; Maeda Y; Konaka H; Koh E; Namiki M
Anticancer Res; 2010 Jul; 30(7):3077-81. PubMed ID: 20683058
[TBL] [Abstract][Full Text] [Related]
28. Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial.
James ND; Caty A; Payne H; Borre M; Zonnenberg BA; Beuzeboc P; McIntosh S; Morris T; Phung D; Dawson NA
BJU Int; 2010 Oct; 106(7):966-73. PubMed ID: 20840318
[TBL] [Abstract][Full Text] [Related]
29. Cabazitaxel for the treatment of castration-resistant prostate cancer.
Agarwal N; Sonpavde G; Sartor O
Future Oncol; 2011 Jan; 7(1):15-24. PubMed ID: 21174534
[TBL] [Abstract][Full Text] [Related]
30. A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy.
Beer TM; Ryan C; Alumkal J; Ryan CW; Sun J; Eilers KM
Anticancer Drugs; 2010 Apr; 21(4):433-8. PubMed ID: 20016365
[TBL] [Abstract][Full Text] [Related]
31. Castration refractory prostate cancer: cinderella finally comes to the ball.
Chowdhury S; Harper P; Powles T
Onkologie; 2010; 33(12):655-6. PubMed ID: 21124035
[No Abstract] [Full Text] [Related]
32. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.
Pili R; Häggman M; Stadler WM; Gingrich JR; Assikis VJ; Björk A; Nordle O; Forsberg G; Carducci MA; Armstrong AJ
J Clin Oncol; 2011 Oct; 29(30):4022-8. PubMed ID: 21931019
[TBL] [Abstract][Full Text] [Related]
33. Chemotherapy-based treatment for castration-resistant prostate cancer.
Seruga B; Tannock IF
J Clin Oncol; 2011 Sep; 29(27):3686-94. PubMed ID: 21844499
[TBL] [Abstract][Full Text] [Related]
34. Satraplatin: leading the new generation of oral platinum agents.
Bhargava A; Vaishampayan UN
Expert Opin Investig Drugs; 2009 Nov; 18(11):1787-97. PubMed ID: 19888874
[TBL] [Abstract][Full Text] [Related]
35. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
36. Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer.
Armstrong AJ; George DJ
Prostate Cancer Prostatic Dis; 2010 Jun; 13(2):108-16. PubMed ID: 20066005
[TBL] [Abstract][Full Text] [Related]
37. The role of IMiDs alone or in combination in prostate cancer.
Nabhan C; Petrylak DP
Clin Genitourin Cancer; 2012 Sep; 10(3):141-6. PubMed ID: 22608152
[TBL] [Abstract][Full Text] [Related]
38. Actual chemotherapeutical possibilities in hormone-refractory prostate cancer (HRPC) patients.
Prezioso D; Galasso R; Di Martino M; Iapicca G; Annunziata E; Iacono F
Anticancer Res; 2007; 27(2):1095-104. PubMed ID: 17465249
[TBL] [Abstract][Full Text] [Related]
39. Drug resistance in metastatic castration-resistant prostate cancer.
Seruga B; Ocana A; Tannock IF
Nat Rev Clin Oncol; 2011 Jan; 8(1):12-23. PubMed ID: 20859283
[TBL] [Abstract][Full Text] [Related]
40. Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer.
Mardjuadi F; Medioni J; Kerger J; D'Hondt L; Canon JL; Duck L; Musuamba F; Oudard S; Clausse M; Moxhon A; Machiels JP
Cancer Chemother Pharmacol; 2012 Aug; 70(2):293-303. PubMed ID: 22752248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]